Arovella Therapeutics Ltd
ASX:ALA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.081
0.195
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALA stock under the Base Case scenario is 0.01 AUD. Compared to the current market price of 0.18 AUD, Arovella Therapeutics Ltd is Overvalued by 96%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Arovella Therapeutics Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Arovella Therapeutics Ltd
Balance Sheet Decomposition
Arovella Therapeutics Ltd
Current Assets | 13.2m |
Cash & Short-Term Investments | 12.7m |
Other Current Assets | 439.2k |
Non-Current Assets | 131.1k |
PP&E | 131.1k |
Other Non-Current Assets | -10 |
Current Liabilities | 2m |
Accounts Payable | 1.8m |
Other Current Liabilities | 215.7k |
Non-Current Liabilities | 15.9k |
Other Non-Current Liabilities | 15.9k |
Earnings Waterfall
Arovella Therapeutics Ltd
Revenue
|
155.7k
AUD
|
Cost of Revenue
|
0
AUD
|
Gross Profit
|
155.7k
AUD
|
Operating Expenses
|
-8.9m
AUD
|
Operating Income
|
-8.7m
AUD
|
Other Expenses
|
-8.6k
AUD
|
Net Income
|
-8.7m
AUD
|
Free Cash Flow Analysis
Arovella Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
ALA Profitability Score
Profitability Due Diligence
Arovella Therapeutics Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Arovella Therapeutics Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ALA Solvency Score
Solvency Due Diligence
Arovella Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Arovella Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALA Price Targets Summary
Arovella Therapeutics Ltd
Dividends
Current shareholder yield for ALA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
Contact
IPO
Employees
Officers
The intrinsic value of one ALA stock under the Base Case scenario is 0.01 AUD.
Compared to the current market price of 0.18 AUD, Arovella Therapeutics Ltd is Overvalued by 96%.